Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer’s disease: risks or benefits

References

• Ballard CG, Margallo-Lana M, Fossey J et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J. Clin. Psychiatry62, 631–636 (2001).
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Steinebrg M, Tschanz JT. Mental and behavioural disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry157, 708–714 (2000).
   PubMed Web of Science ®Google Scholar
• Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioural changes in Alzheimer’s disease. Neurology46, 130–135 (1996).
   PubMed Web of Science ®Google Scholar
• O’Donnell BF, Drachmen DA, Barnes HJ, Petersen KE, Swearer JM, Lew RA. Incontinence and troublesome behaviours predict institutionalization in dementia. J. Geriatr. Psych. Neurol.5, 45–52 (1992).
   PubMedGoogle Scholar
• Kaufer D. Treatment of behavioral symptoms in Alzheimer’s disease. Am. Acad. Neurol.35(9), 846–850 (2000).
   Google Scholar
• Mintzer JE, Brawman-Mintzer O, Mirski D, Barkin K. Anxiety in the behavioral and psychological symptoms of dementia (BPSD). Int. Psychogeriatrics12(Suppl.1), 139–142 (2000).
   Web of Science ®Google Scholar
• Feifel D. Psychopharmacology in the acute setting: review and proposed guidelines. Psychiatric TimesXVIII(5) (2001).
   Google Scholar
• Folstein MF, Bylsma FW. Noncognitive symptoms of Alzheimer disease. In: Alzheimer Disease, 2nd Edition. Terry RD, Katzmann R, Bick L, Sisodia SS (Eds), Lippincott Williams & Wilkins, PA, USA,25–37 (1999).
   Google Scholar
• Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorder. Consensus statement of the American Geriatric Association for Geriatric Psychiatry, the Alzheimer’s Association and the American Geriatrics society. JAMA278, 1363–1371 (1997).
   PubMed Web of Science ®Google Scholar
• Devanand DP, Marder K, Michaels KS et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer’s Disease. Am. J. Psychiatry155, 1512–1520 (1998).
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology53, 946–955 (1999).
   PubMed Web of Science ®Google Scholar
• Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double-blind trial. J. Clin. Psychiatry60, 107–115 (1999).
   PubMed Web of Science ®Google Scholar
• McManus DQ, Arvanitis LA, Kowalcyk BB and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J. Clin. Psychiatry60, 292–298 (1999).
   PubMed Web of Science ®Google Scholar
• Street J, Clark S, Gannon KS et al. for the HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch. Gen. Psychiatry57, 968–976 (2000).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Ryan M, Porsteinsson AP, Loy R, Schneider LS. Pharmacologic therapy for behavioral symptoms of Alzheimer’s disease. Clin. Geriatr. Med.17, 359–376 (2001).
   PubMedGoogle Scholar
• Aarsland D, Larsen JP, Cummings JL. Mortality and hallucination in Parkinson’s disease: a four-year longitudinal study. J. Neuropsych. Clin. Neurosci.9, 642 (1997).
   Google Scholar
• Stern RG, Duffelmeyer ME, Zemishlani Z, Davidson M. The use of benzodiazepines in the management of behavioral symptoms in dementia patients. Psychiatr. Clin. North Am.14, 375–384 (1991).
   PubMed Web of Science ®Google Scholar
• Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer’s disease. Neurology48(Suppl. 6), S17–S24 (1997).
   Google Scholar
• Coccaro EF, Kramer E, Zemishlany Z et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am. J. Psychiatry147, 1640–1645 (1990).
   PubMedGoogle Scholar
• Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J. Am. Geriatr. Soc.38, 553–583 (1990).
   PubMed Web of Science ®Google Scholar
• Terry RD, Katzman R, Bick KL, Sisodia SS. Alzheimer Disease. Lippincott Williams and Wilkins, PA, USA (2000).
   Google Scholar
• Devanand D, Sackeim H, Brown R, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer’s disease. Arch. Neurol.46, 854–857 (1989).
   PubMedGoogle Scholar
• Wood S, Cummings JL, Hsu MA et al. The use of the neuro-psychiatric inventory in nursing home residents. Characterization and measurement. Am. J. Geriatr. Psychiatry8, 75–83 (2000).
   PubMed Web of Science ®Google Scholar
• Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am. Fam. Physician67(11), 2335–2340 (2003).
   PubMedGoogle Scholar
• Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert Consensus Panel for using antipsychotic drugs in older patients. Using antipsychotic agents in older patients. J. Clin. Psychiatry65(Suppl. 2), 5–99 (2004).
   PubMed Web of Science ®Google Scholar
• Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trial of risperidone in the treatment of aggression, agitation and psychosis of dementia. J. Clin. Psychiatry64(2), 134–143 (2003).
   PubMed Web of Science ®Google Scholar
• Meehan K, Wang H, David S et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology26, 494–504 (2002).
   PubMed Web of Science ®Google Scholar
• Lee PE, Gill SS, Freedman M, Bronksill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia: systematic review. Br. Med. J.329(7457), 75 (2004).
   PubMed Web of Science ®Google Scholar
• Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapin in long term care patients with dementia. J. Am. Med. Dir. Assoc.4(4), 183–188 (2003).
   PubMedGoogle Scholar
• Hwang JP, Yang CH, Lee TW, Tsai SJ. The efficacy and safety of olanzapine for the treatment of geriatric psycosis. J. Clin. Psychopharmacol.23(2), 113–118 (2003).
   PubMedGoogle Scholar
• Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilites. J. Clin. Psychiatry64(6), 726–730 (2003).
   PubMed Web of Science ®Google Scholar
• Schatz RA. Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. Ann. Pharamacother.37(9), 1321–1324 (2003).
   PubMedGoogle Scholar
• Cummings JL. Neuropsychiatric symptoms and their treatments in patients with moderate to severe dementia. AAN, CA, USA, 3DS. 1–11 (2004).
   Google Scholar
• Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry161(6), 1113–1135 (2004).
   PubMed Web of Science ®Google Scholar
• Gill SS, Rochon PA, Herrmann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Br. Med. J.330, 7445–7489 (2005).
   Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA294(15), 1934–1943 (2005).
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Canadian Medical Association journal170(9), 1395 (2004).
   PubMed Web of Science ®Google Scholar
• De Deyn PP, Carrasco MM, Deberdt W et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry19(2), 115–126 (2004).
   PubMed Web of Science ®Google Scholar
• Hermann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am. J. Psychiatry161, 1113–1115 (2004).
   PubMedGoogle Scholar
• Mowat D. CSM warning on atypical psychotics and stroke may be detrimental for dementia. Br. Med. J.328, 1262 (2004).
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G.Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J. Neurol.252(10), 1186–1193 (2005).
   PubMedGoogle Scholar